Breakthroughs in Atopic Dermatitis, with Linda Stein Gold, MD

Linda Stein Gold, MD, FAAD, discusses the late-breaking tapinarof cream 1% data from a new analysis of the ADORING-3 clinical trial. Interview recorded at the 2025 American Academy of Dermatology conference in Orlando, Florida. 

Topics discussed include:

• Key insights from the new analysis of the ADORING-3 clinical trial on the use of tapinarof cream, 1% in patients with atopic dermatitis. 
• Long-term safety and efficacy of tapinarof cream.
• How tapinarof cream differs from existing treatment options.
• Impacts on clinical practice.